FDA Authorizes J&J's OTTAVA Robotic Surgical System, Entering $7B Market
JNJ sits 55% above its 52-week low of $162.78.
Summary
The FDA granted De Novo authorization for Johnson & Johnson's OTTAVA robotic surgical system, clearing it for multiple general surgery procedures including gastric bypass and cholecystectomy. This marks J&J's entry into the competitive soft-tissue robotics market dominated by Intuitive Surgical. The system's table-integrated design and smaller footprint could differentiate it in crowded operating rooms. A commercial launch with select U.S. customers is planned, with an ongoing trial for hernia repair. The approval adds a new growth vector to J&J's MedTech segment, which already posted strong Q2 results. Success will depend on adoption rates and expansion into additional indications.
At the time of this announcement, JNJ was trading at $252.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $603.3B. The 52-week trading range was $162.78 to $269.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.